TEVA-ATENOLOL TABLET

Quốc gia: Canada

Ngôn ngữ: Tiếng Anh

Nguồn: Health Canada

Thành phần hoạt chất:

ATENOLOL

Sẵn có từ:

TEVA CANADA LIMITED

Mã ATC:

C07AB03

INN (Tên quốc tế):

ATENOLOL

Liều dùng:

100MG

Dạng dược phẩm:

TABLET

Thành phần:

ATENOLOL 100MG

Tuyến hành chính:

ORAL

Các đơn vị trong gói:

100/500

Loại thuốc theo toa:

Prescription

Khu trị liệu:

BETA-ADRENERGIC BLOCKING AGENTS

Tóm tắt sản phẩm:

Active ingredient group (AIG) number: 0113847001; AHFS:

Tình trạng ủy quyền:

APPROVED

Ngày ủy quyền:

2002-05-15

Đặc tính sản phẩm

_TEVA ATENOLOL (Atenolol) _
_ _
_Page 1 of 32_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
TEVA-ATENOLOL
Atenolol Tablets
Tablets, 50 mg and 100 mg, Oral
B.P.
Beta-adrenergic receptor blocking agent
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
Canada, M1B 2K9
www.tevacanada.com
Submission Control Number: 278032
Date of Initial Authorization:
NOV 22, 2017
Date of Revision:
FEB 16, 2024
_TEVA ATENOLOL (Atenolol) _
_ _
_Page 2 of 32 _
RECENT MAJOR LABEL CHANGES
N/A
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
..............................................................................................
2
TABLE OF
CONTENTS………………………………………………………………………………………………………………2
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................................
4
1 INDICATIONS
..........................................................................................................................
4
1.1 Pediatrics
.............................................................................................................................
4
1.2 Geriatrics
.............................................................................................................................
4
2 CONTRAINDICATIONS
............................................................................................................
4
3 SERIOUS WARNINGS AND PRECAUTIONS BOX
.......................................................................
5
4 DOSAGE AND ADMINISTRATION
........................................................................................
5
4.1 Dosing Considerations
.....................................................................................................
5
4.2 Recommended Dose and Dosage Adjustment
………………………………………………………………5
4.4 Administration
...